View in EDS

Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer.

Saved in:
Bibliographic Details
Title: Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer.
Authors: Konecny, Gottfried1 (AUTHOR), Moore, Kathleen2 (AUTHOR), Lebreton, Coriolan3 (AUTHOR), Weroha, Saravut4 (AUTHOR), Marin, Margarita Romeo5 (AUTHOR), McAvan, Lucy6 (AUTHOR), Colombo, Nicoletta7 (AUTHOR), O'Malley, David8 (AUTHOR), Coffman, Lan9 (AUTHOR), Roszak, Andrzej10 (AUTHOR), Shapira-Frommer, Ronnie11 (AUTHOR), Lalisang, Roy12 (AUTHOR), Cibula, David13 (AUTHOR), Barquin, Arantzazu14 (AUTHOR), Glasspool, Rosalind15 (AUTHOR), Stec, James16 (AUTHOR), Li, Lingling16 (AUTHOR), Method, Michael16 (AUTHOR), Hardy-Bessard, Anne Claire17 (AUTHOR), Van Gorp, Toon18 (AUTHOR)
Source: Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS11-S12. 2p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2024.07.023